Empagliflozin and kinetics of renal glucose transport in healthy individuals and individuals with type 2 diabetes

Diabetes

Volumn 66, Issue 7, 2017, Pages 1999-2006

  Al Jobori, Hussein ^a   Daniele, Giuseppe ^a   Cersosimo, Eugenio ^a   Triplitt, Curtis ^a   Mehta, Rucha ^a   Norton, Luke ^a   DeFronzo, Ralph A ^a   Abdul Ghani, Muhammad ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORIDE; CREATININE; EMPAGLIFLOZIN; GLUCOSE; HEMOGLOBIN A1C; POTASSIUM; SODIUM; SODIUM GLUCOSE COTRANSPORTER 2; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSE BLOOD LEVEL; GLUCOSIDE;

ABDOMINAL PAIN; ADULT; ARTICLE; BACKACHE; BODY WEIGHT; CHLORIDE URINE LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; CREATININE URINE LEVEL; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HEADACHE; HEART PALPITATION; HUMAN; KIDNEY TUBULE ABSORPTION; MYCOSIS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; POTASSIUM URINE LEVEL; PRIORITY JOURNAL; RASH; SODIUM EXCRETION; SODIUM URINE LEVEL; TREATMENT DURATION; URINARY EXCRETION FRACTION; URINARY TRACT INFECTION; URINE VOLUME; VOMITING; WEAKNESS; XEROSTOMIA; ANTAGONISTS AND INHIBITORS; CASE CONTROL STUDY; DIABETES MELLITUS, TYPE 2; GLUCOSE CLAMP TECHNIQUE; GLUCOSURIA; KIDNEY; KINETICS; MALE; METABOLISM; MIDDLE AGED;

BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE; GLUCOSE CLAMP TECHNIQUE; GLUCOSIDES; GLYCOSURIA; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY; KINETICS; MALE; MIDDLE AGED; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 85021083050     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db17-0100     Document Type: Article

References (16)

1. Abdul-Ghani MA, Norton L, Defronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev 2011;32: 515-531
2. Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev 2011;91: 733-794
3. Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 2014; 124: 509-514
4. Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodiumglucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 2014;124: 499-508
5. Merovci A, Mari A, Solis C, et al. Dapagliflozin lowers plasma glucose concentration and improves β-Cell function. J Clin Endocrinol Metab 2015;100: 1927-1932
6. DeFronzo RA, Hompesch M, Kasichayanula S, et al. Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care 2013;36: 3169-3176
7. Sha S, Devineni D, Ghosh A, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 2011;13: 669-672
8. Polidori D, Sha S, Ghosh A, Plum-Mörschel L, Heise T, Rothenberg P. Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 2013;98: E867-E871
9. Komoroski B, Vachharajani N, Boulton D, et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 2009;85: 520-526
10. Liang Y, Arakawa K, Ueta K, et al. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS One 2012;7: E30555
11. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: A method for quantifying insulin secretion and resistance. Am J Physiol 1979;237: E214-E223
12. Zhao X, Cui Y, Zhao S, et al. Pharmacokinetic and pharmacodynamic properties and tolerability of single- and multiple-dose once-daily empagliflozin, a sodium glucose cotransporter 2 inhibitor, in Chinese patients with type 2 diabetes mellitus. Clin Ther 2015;37: 1493-1502
13. Abdul-Ghani MA, DeFronzo RA, Norton L. Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans. Diabetes 2013;62: 3324-3328
14. DeFronzo RA, Lewin A, Patel S, et al. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care 2015;38: 384-393
15. Rosenstock J, Hansen L, Zee P, et al. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: A randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care 2015;38: 376-383
16. Farber SJ, Berger EY, Earle DP. Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose. J Clin Invest 1951;30: 125-129